Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2024-05-08 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Extension of Voluntary Suspension 1 page 126.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 9 May 2024 from HeraMED Limited requesting an extension of voluntary suspension of its securities. It references Listing Rule 17.2 and mentions the suspension is due to ongoing negotiations for additional funding and potential Board changes. The document is short (1683 characters) and is a formal request for suspension, not a financial report or detailed disclosure. It does not contain financial data, audit information, or detailed management discussion. It is clearly an announcement related to capital/financing activities and Board changes but primarily focuses on the suspension request tied to financing and Board changes. Given the focus on financing and suspension, the best fitting category is Capital/Financing Update (CAP).
2024-05-08 English
ASIC Approval for Extension to Hold 2024 AGM 1 page
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 May 2024 regarding ASIC approval for an extension to hold the 2024 Annual General Meeting (AGM) of HeraMED Limited. It references the Corporations Act 2001 and the extension granted by ASIC to hold the AGM by 20 June 2024. The announcement states that the original AGM Notice of Meeting will be superseded by an updated Notice of Meeting to be sent to shareholders shortly. The document does not contain the AGM materials themselves, nor does it include financial statements or detailed report content. It is a regulatory announcement about the timing and procedural extension for the AGM, not the AGM information or the Annual Report itself. The document length is short (2854 characters), consistent with an announcement rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement about the AGM extension.
2024-05-07 English
Final Director's Interest Notice - RW 2 pages 297.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares and options, and the date the director ceased to be a director. This type of document is a report of personal share transactions or holdings by a company director. It matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on director interests, not a full financial report or announcement of a report. Therefore, the correct classification is DIRS.
2024-05-02 English
Non-Executive Director resignation 1 page 100.3KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 1 May 2024 regarding the resignation of a Non-Executive Director, Dr Ron Weinberger, from HeraMED Limited. It discusses management changes and mentions the upcoming appointment of a new director. There is no financial data, no report attached or referenced, and the content focuses solely on board/management changes. According to the filing definitions, announcements about changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short and does not contain financial statements or other report types, so it is not an Annual Report or Interim Report. Therefore, the correct classification is MANG with high confidence.
2024-04-30 English
Notice of Annual General Meeting/Proxy Form 23 pages 2.9MB
AGM Information Classification · 100% confidence The document is an ASX announcement dated 30 April 2024 regarding the Notice of the 2024 Annual General Meeting (AGM) of HeraMED Limited. It includes a Letter to Shareholders, the Notice of Meeting, Proxy Form, and explanatory statements related to the AGM. The content focuses on informing shareholders about the upcoming AGM, voting procedures, and related documents. There is no detailed financial data or full financial performance report included. The document is comprehensive and about the AGM materials but does not contain the actual Annual Report or financial statements themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM.
2024-04-29 English
Extension of Voluntary Suspension 1 page 100.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 April 2024, requesting an extension of voluntary suspension of trading of the company's securities. It mentions ongoing discussions for proposed financing and Board changes but does not contain financial statements or detailed financial data. The document is short (1719 characters) and serves as a regulatory announcement about trading suspension and upcoming events rather than a full report or detailed update. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.